OncoMatch/Clinical Trials/NCT04084730
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
Is NCT04084730 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for invasive ductal breast carcinoma.
The purpose of this study is to determine if the dose of radiation therapy that is effective in producing a treatment response, delivered over a shorter treatment period, is a safe approach that causes few or mild side effects in women with newly diagnosed breast cancer or DCIS who have had a lumpectomy procedure.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 positive
estrogen-receptor positive (ER+)
Excluded: BRCA1 mutation
if a patient is tested and is found to be a mutation carrier, she would be excluded from the study
Excluded: BRCA2 mutation
if a patient is tested and is found to be a mutation carrier, she would be excluded from the study
Disease stage
Required: Stage I
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: radiation therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Norwalk Hospital · Norwalk, Connecticut
- Baptist Alliance Miami Cancer Institute · Miami, Florida
- Memorial Sloan Kettering Basking Ridge · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth · Middletown, New Jersey
- Memorial Sloan Kettering Bergen · Montvale, New Jersey
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify